Non-cystic fibrosis bronchiectasis.

bronchiectasis is a chronic, debilitating condition characterised by persistent cough, excessive sputum production and recurrent chest infections. The precise prevalence is unknown, but figures quoted vary from about 4 × 105 aged 18–34 years to 272 × 105 aged 75 years and over.2,3 Pathologically, there is abnormal permanent dilatation of the airways. This leads to impaired mucociliary clearance, which in turn leads to a vicious cycle of bacterial colonisation in normally sterile airways and excessive bronchial inflammation. This review explores current clinical practice for this complex condition.

[1]  Megan L. Martin,et al.  Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. , 2011, Respiratory medicine.

[2]  B. Karadag,et al.  Differences and similarities in non-cystic fibrosis bronchiectasis between developing and affluent countries. , 2011, Paediatric respiratory reviews.

[3]  L. Bahadorzadeh,et al.  Surgical Management of Bronchiectasis: Analysis of 277 Patients , 2010, The Thoracic and cardiovascular surgeon.

[4]  A. Hill,et al.  Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis , 2009, European Respiratory Journal.

[5]  A. Hill,et al.  Assessing response to treatment of exacerbations of bronchiectasis in adults , 2008, European Respiratory Journal.

[6]  A. Hasani,et al.  Domiciliary humidification improves lung mucociliary clearance in patients with bronchiectasis , 2008, Chronic respiratory disease.

[7]  S. Anderson,et al.  Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis , 2008, European Respiratory Journal.

[8]  N. Müller,et al.  Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. , 2008, American journal of respiratory and critical care medicine.

[9]  J. Soriano,et al.  Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. , 2007, Chest.

[10]  P. King,et al.  Microbiologic follow-up study in adult bronchiectasis. , 2007, Respiratory medicine.

[11]  R. Wilson,et al.  Aetiology in adult patients with bronchiectasis. , 2007, Respiratory medicine.

[12]  J. Bradley,et al.  Acapella ® versus `usual airway clearance' during acute exacerbation in bronchiectasis: a randomized crossover trial , 2007, Chronic respiratory disease.

[13]  I. Zeng,et al.  A randomized evaluation of the acute efficacy, acceptability and tolerability of Flutter and active cycle of breathing with and without postural drainage in non-cystic fibrosis bronchiectasis , 2007, Chronic respiratory disease.

[14]  P. King,et al.  Characterisation of the onset and presenting clinical features of adult bronchiectasis. , 2006, Respiratory medicine.

[15]  S. Fowler,et al.  Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics , 2006, European Respiratory Journal.

[16]  G. Fischer,et al.  Non-cystic-fibrosis bronchiectasis: a perspective from South America. , 2006, Paediatric respiratory reviews.

[17]  R. Wilson,et al.  The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis , 2006, European Respiratory Journal.

[18]  M. Martínez-García,et al.  Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. , 2006, Respiratory medicine.

[19]  R. Wilson,et al.  Non-tuberculous mycobacteria in patients with bronchiectasis , 2005, Thorax.

[20]  M. Martínez-García,et al.  Quality-of-life determinants in patients with clinically stable bronchiectasis. , 2005, Chest.

[21]  G. Oster,et al.  Prevalence and Economic Burden of Bronchiectasis , 2005 .

[22]  C. Byrnes,et al.  New Zealand national incidence of bronchiectasis “too high” for a developed country , 2005, Archives of Disease in Childhood.

[23]  I. Bradbury,et al.  Airway Clearance in Bronchiectasis: A Randomized Crossover Trial of Active Cycle of Breathing Techniques versus Acapella® , 2005, Respiration.

[24]  M. Chan-yeung,et al.  Inhaled fluticasone in bronchiectasis: a 12 month study , 2005, Thorax.

[25]  P. Suñé,et al.  Inhaled Tobramycin in Non—Cystic Fibrosis Patients with Bronchiectasis and Chronic Bronchial Infection with Pseudomonas Aeruginosa , 2005, The Annals of pharmacotherapy.

[26]  S. Anderson,et al.  Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: Effect on lung function, health status and sputum , 2005, Respirology.

[27]  J. Wedzicha,et al.  Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[28]  B. Morrissey,et al.  Bronchiectasis: sex and gender considerations. , 2004, Clinics in chest medicine.

[29]  J. Elborn,et al.  Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. , 2003, European journal of internal medicine.

[30]  A. Gözübüyük,et al.  Surgical management of bronchiectasis: analysis and short-term results in 238 patients. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[31]  P. Cole,et al.  Effect of osmolality on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum , 2003, Respirology.

[32]  D. Smith,et al.  Randomised crossover study of the Flutter device and the active cycle of breathing technique in non-cystic fibrosis bronchiectasis , 2002, Thorax.

[33]  R. Rodríguez-Roisín,et al.  Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors , 2002, Thorax.

[34]  J. Bradley,et al.  THE CURRENT PHYSIOTHERAPY MANAGEMENT OF PATIENTS WITH BRONCHIECTASIS: A UK SURVEY , 2002, International journal of clinical practice.

[35]  C. Agustí,et al.  Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. , 2001, American journal of respiratory and critical care medicine.

[36]  S. Anderson,et al.  The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. , 2001, Chest.

[37]  M. Keogan,et al.  An investigation into causative factors in patients with bronchiectasis. , 2000, American journal of respiratory and critical care medicine.

[38]  R. Stockley,et al.  Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. , 2000, The American journal of medicine.

[39]  P. Ho,et al.  A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis. , 1999, The European respiratory journal.

[40]  G. Sampol,et al.  Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. , 1999, Respiratory medicine.

[41]  S. Anderson,et al.  Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. , 1999, American journal of respiratory and critical care medicine.

[42]  Wai Lam,et al.  A pilot study of low-dose erythromycin in bronchiectasis. , 1999, The European respiratory journal.

[43]  K. Yuen,et al.  Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. , 1998, American journal of respiratory and critical care medicine.

[44]  S. Durham,et al.  Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis , 1998, Thorax.

[45]  A. O'donnell,et al.  Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. , 1998, Chest.

[46]  P. Jones,et al.  Validation of the St. George's Respiratory Questionnaire in bronchiectasis. , 1997, American journal of respiratory and critical care medicine.

[47]  D. Symmons,et al.  Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. , 1997, British journal of rheumatology.

[48]  M. Nicotra,et al.  Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. , 1995, Chest.

[49]  J. Bernaudin,et al.  Ciliary abnormalities in bronchial epithelium of smokers, ex-smokers, and nonsmokers. , 1995, American journal of respiratory and critical care medicine.

[50]  J. Elborn,et al.  Inhaled steroids in patients with bronchiectasis. , 1992, Respiratory medicine.

[51]  J. Fleming,et al.  Humidification as an adjunct to chest physiotherapy in aiding tracheo-bronchial clearance in patients with bronchiectasis. , 1992, Respiratory medicine.

[52]  H. Todd,et al.  Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. , 1990, The Quarterly journal of medicine.

[53]  R. Stockley,et al.  Effect of short and long term antibiotic response on lung function in bronchiectasis. , 1986, Thorax.

[54]  S. Siegelman,et al.  Computed Tomography of Bronchiectasis , 1982, Journal of computer assisted tomography.

[55]  H. Raafat,et al.  Cephaloridine compared with penicillin and streptomycin in chronic purulent bronchitis. Controlled trials of increasing dosage of cephaloridine. , 1967, British journal of diseases of the chest.

[56]  G. Jackson,et al.  ADVERSE REACTIONS TO TETRACYCLINE, PENICILLIN AND AN OLEANDOMYCIN-PENICILLIN MIXTURE USED IN THE LONG-TERM THERAPY OF CHRONIC PULMONARY DISEASE , 1962, The American journal of the medical sciences.

[57]  J. Maurer Trends and Burden of Bronchiectasis-Associated Hospitalizations in the United States, 1993-2006 , 2011 .

[58]  M. Raza A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis , 2010 .

[59]  A. Arroliga,et al.  Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasis , 2010 .

[60]  N. Uzuner,et al.  A neglected problem of developing countries: Noncystic fibrosis bronchiectasis , 2009, Annals of thoracic medicine.

[61]  Christina C. Chang,et al.  Pneumococcal vaccines for children and adults with bronchiectasis. , 2007, The Cochrane database of systematic reviews.

[62]  J. May,et al.  The Disease-Modifying Effects of Twice-Weekly Oral Azithromycin in Patients with Bronchiectasis , 2005, Treatments in respiratory medicine.

[63]  R. Niven,et al.  Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. , 2005, Respiratory medicine.

[64]  R. Wilson,et al.  Prophylactic antibiotic treatment of bronchiectasis with azithromycin. , 2004, Thorax.

[65]  A. Sheikh,et al.  Short acting beta-2 agonists for bronchiectasis. , 2003, The Cochrane database of systematic reviews.

[66]  A. Sheikh,et al.  Long-acting beta-2-agonists for bronchiectasis. , 2001, The Cochrane database of systematic reviews.

[67]  A. Crockett,et al.  Mucolytics for bronchiectasis. , 2001, The Cochrane database of systematic reviews.

[68]  Kenneth Meyer,et al.  Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. , 2000, American journal of respiratory and critical care medicine.

[69]  S. Simon,et al.  Aerosolized antibiotics in mechanically ventilated patients: delivery and response. , 1998, Critical care medicine.

[70]  P. Cole Inflammation: a two-edged sword--the model of bronchiectasis. , 1986, European journal of respiratory diseases. Supplement.

[71]  J. V. van Noord,et al.  Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime. , 1983, The Journal of antimicrobial chemotherapy.

[72]  PROLONGED antibiotic treatment of severe bronchiectasis; a report by a subcommittee of the Antibiotics Clinical Trials (non-tuberculous) Committee of the Medical Research Council. , 1957, British medical journal.

[73]  W. Warner BRONCHIECTASIS: AETIOLOGY, DIAGNOSIS AND TREATMENT. , 2022, Canadian Medical Association journal.